Pfizer (PFE) DIvidends Date & History

Key Takeaways

• Pfizer offers a forward dividend yield of 6.53%, significantly higher than many pharmaceutical peers.
• Quarterly dividend of $0.43 per share, equating to an annual payout of $1.72, paid consistently every three months.
• 15-year streak of consecutive dividend increases demonstrates commitment to shareholders.
• Payout ratio stands at approximately 53% on a non-GAAP basis, though over 125% on GAAP earnings, raising some sustainability questions.
• Free cash flow (FCF, a measure of cash generated after capital expenditures) recently covers dividends closely, with minor exceedance in 2025.
• Next ex-dividend date is May 8, 2026, with payment on June 12, 2026.

Dividend Overview

Pfizer (PFE) maintains a robust quarterly dividend policy, distributing $0.43 per share each quarter for an annual total of $1.72. This delivers a forward yield of 6.53% as of early May 2026, positioning it as a high-yield option in the pharmaceutical sector. Payments occur reliably in March, June, September, and December, reflecting the company's strategy to return significant capital to shareholders amid post-pandemic revenue adjustments. While not a rapid dividend growth stock, Pfizer's profile appeals to income-focused investors seeking elevated yields from a blue-chip name with a diversified drug portfolio.

Dividend History and Growth

Pfizer has a strong track record of dividend payments, with quarterly distributions dating back decades and no recent cuts. The company boasts a 15-year streak of consecutive annual increases, underscoring its long-term strategy of balancing R&D investments with shareholder returns. Over the past five years, dividends have grown at an average rate of 3.19%, with the most recent hike maintaining the $0.43 quarterly rate declared for Q2 2026. This consistency stems from Pfizer's focus on stable cash flows from blockbuster drugs, even as it navigates patent expirations and pipeline developments.

Dividend Sustainability and Payout Ratio

Pfizer's dividend sustainability draws mixed signals. The non-GAAP (non-generally accepted accounting principles, which exclude one-time items) payout ratio is a manageable 53.25%, indicating ample coverage from adjusted earnings. However, on a GAAP basis, it exceeds 125%, reflecting pressures from declining COVID-related revenues and high R&D costs. Free cash flow provided $9.076 billion in 2025 against $9.771 billion in dividends, a slight shortfall but supported by overall liquidity and manageable debt levels. Management's pipeline investments in oncology and vaccines bolster long-term stability, though investors monitor earnings recovery closely.

Dividend Compared to Peers

Pfizer's 6.53% yield outpaces key pharmaceutical peers. JNJ (Johnson & Johnson) offers around 2.6%, while MRK (Merck) yields 2-3%, and ABBV (AbbVie) approximately 3.25%. This premium reflects Pfizer's lower stock price post-COVID but also highlights its higher payout intensity relative to more conservatively yielding rivals with stronger growth profiles.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research today.

Is This Stock Attractive for Dividend Investors?

Pfizer appeals to income investors prioritizing high current yields over aggressive growth, particularly those comfortable with pharmaceutical sector volatility. Its 6.53% yield provides substantial passive income, outshining many dividend aristocrats, and the 15-year growth streak suits moderate growth seekers. However, conservative investors may hesitate due to the elevated GAAP payout ratio and recent FCF pressures, preferring peers like JNJ with lower yields but superior coverage. Long-term holders valuing Pfizer's pipeline in immunology and oncology could find the combination of yield and recovery potential balanced, though cyclical revenue risks warrant diversification. Overall, it fits portfolios emphasizing yield in large-cap healthcare without chasing speculative growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations